Johnson & Johnson

Summary

Johnson & Johnson remains a defensive healthcare leader with an impeccable 64-year history of dividend growth and a fortress balance sheet. However, current valuation multiples are highly stretched (P/E ~30) and the 2.05% yield offers limited immediate income. Existing shareholders should maintain positions for stability, but new investors may want to monitor for a better entry point that provides a higher yield and margin of safety.

Sector Context

Johnson & Johnson is a diversified, premier global healthcare conglomerate that researches, develops, and manufactures pharmaceuticals and medical devices. In the healthcare sector, large-cap pharmaceutical companies face inherent long-term structural risks like patent cliffs and regulatory pricing pressures, making robust balance sheets and massive acquisition capabilities essential for sustaining long-term dividend growth.

📊 Strategy Analysis

• • Unparalleled financial scale with a AAA-rated balance sheet and strong Free Cash Flow covering the dividend with a safe 54.8% cash flow payout ratio.
• • Impeccable 64-year track record of consecutive dividend increases, cementing its position as a premier defensive dividend holding.
• • Massive scale and financial resources allow the company to aggressively acquire late-stage pipelines to offset incoming patent expirations.

⚠ What to Watch

• • Current valuation is highly stretched with a trailing P/E of 29.9, well above the strategy's target range of 8-15x and exceeding typical healthcare valuations.
• • The trailing dividend yield of 2.05% falls short of the minimum 3% threshold typically required for new income-focused positions.
• • Faces significant structural headwinds including patent cliffs for key blockbusters (Stelara, Xarelto), IRA Medicare price mandates implemented in 2026, and open-ended talc mass tort litigation.